Evidence map›Paper›PMID 17470278›Full record

ArticleBMC medical genetics2007

Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes.

Randy J Chandler, Matthew S Tsai, Kenneth Dorko, Jennifer Sloan, Mark Korson, Richard Freeman, Stephen Strom, Charles P Venditti

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
  11. Mitochondrial dysfunction in mut methylmalonic acidemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Randy J ChandlerNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA. rchandler@mail.nih.gov
Matthew S Tsai
Kenneth Dorko
Jennifer Sloan
Mark Korson
Richard Freeman
Stephen Strom
Charles P Venditti
National Human Genome Research Institute · USTufts University · USUniversity of Pittsburgh · USNational Institutes of Health · US

Funding

Investigations of Methylmalonic Acidemia and Related DisordersZ01HG200318 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BIESECKER, LESLIE · 2004 to 2008
$1.6M
LIVER TISSUE PROCUREMENT AND DISTRIBUTION SYSTEMN01DK092310 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI KRESINA, THOMAS · 1999 to 2000
$488k
Intramural NIH HHS Z01 HG200318Intramural NIH HHS Z99 HG999999NIDDK NIH HHS DK-9-2310
6 · The paper itself

Abstract

backgroundMethylmalonic acidemia (MMA), a common organic aciduria, is caused by deficiency of the mitochondrial localized, 5'deoxyadenosylcobalamin dependent enzyme, methylmalonyl-CoA mutase (MUT). Liver transplantation in the absence of gross hepatic dysfunction provides supportive therapy and metabolic stability in severely affected patients, which invites the concept of using cell and gene delivery as future treatments for this condition.

methodsTo assess the effectiveness of gene delivery to restore the defective metabolism in this disorder, adenoviral correction experiments were performed using murine Mut embryonic fibroblasts and primary human methylmalonyl-CoA mutase deficient hepatocytes derived from a patient who harbored two early truncating mutations, E224X and R228X, in the MUT gene. Enzymatic and expression studies were used to assess the extent of functional correction.

resultsPrimary hepatocytes, isolated from the native liver after removal subsequent to a combined liver-kidney transplantation procedure, or Mut murine fibroblasts were infected with a second generation recombinant adenoviral vector that expressed the murine methylmalonyl-CoA mutase as well as eGFP from distinct promoters. After transduction, [1-14C] propionate macromolecular incorporation studies and Western analysis demonstrated complete correction of the enzymatic defect in both cell types. Viral reconstitution of enzymatic expression in the human methylmalonyl-CoA mutase deficient hepatocytes exceeded that seen in fibroblasts or control hepatocytes.

conclusionThese experiments provide proof of principle for viral correction in methylmalonic acidemia and suggest that hepatocyte-directed gene delivery will be an effective therapeutic treatment strategy in both murine models and in human patients. Primary hepatocytes from a liver that was unsuitable for transplantation provided an important resource for these studies.

Indexed as

Gene Transfer TechniquesAdenoviridaeAmino Acid Metabolism, Inborn ErrorsAnimalsBlotting, WesternCell LineChild, PreschoolFibroblastsGenetic TherapyGenetic VectorsHepatocytesHumansMaleMethylmalonic AcidMethylmalonyl-CoA MutaseMiceMethylmalonic AcidMethylmalonyl-CoA Mutase

Identifiers

PMID17470278
PMCPMC1876207
OpenAlexW2159406584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.